SS Innovations’ Robotic Scalpel Reaches Across Continents and Generations

FORT LAUDERDALE, FL – September 10, 2026 – In a series of milestones that blur the lines between healthcare, technology, and global equity, SS Innovations International has provided a powerful update on the expanding reach of its SSi Mantra surgical robotic system. The company’s recent achievements are not merely entries in a corporate ledger; they represent tangible shifts in who can access the most advanced surgical care, where they can receive it, and at what scale. As the developer of a system explicitly designed to be both affordable and accessible, its progress offers a compelling case study in how institutional innovation can directly fuel community wellbeing on a global scale.

“Our advanced, cost-effective SSi Mantra surgical robotic system is benefitting lives globally, one patient at a time, from a 45-day old baby needing kidney surgery in India to a cardiac patient in Sri Lanka,” commented Dr. Sudhir Srivastava, the company's Chairman and CEO. His statement encapsulates the dual narrative at play: one of individual lives transformed and another of a systemic effort to democratize a field long dominated by prohibitive costs.

Robotics for the Many: Redefining Surgical Access

The most profound impact of any innovation is measured by its reach. SS Innovations is strategically expanding its footprint into regions where robotic surgery has been more of an aspiration than a reality. The recent installations in Colombia and Sri Lanka are benchmark examples of this mission in action. In Bucaramanga, Colombia, the SSi Mantra system was used to perform the country’s first Totally Endoscopic Beating-Heart Bypass Surgery. At Kings Hospital Colombo in Sri Lanka, the system’s arrival not only launched the center’s robotic surgery program but was immediately put to work, performing the nation’s first robotic-assisted cardiac surgery and over 25 other procedures in its first three weeks.

This rapid adoption is no accident. It is the result of a deliberate strategy to navigate complex international regulatory pathways. The company secured approval from Colombia’s INVIMA in late 2025 and Sri Lanka’s NMRA in early 2026, demonstrating an ability to meet diverse regulatory standards. This approach, which targets underserved markets while pursuing approvals in major Western markets, allows the organization to build a global presence and gather a wealth of clinical data. By bringing its technology to 12 countries, with a significant base in its home market of India, the company is challenging the long-held paradigm that cutting-edge medical technology is reserved for the world’s wealthiest nations. It is a powerful demonstration of how a cost-effective, high-performance solution can unlock the potential of healthcare institutions globally.

Beyond the Operating Room: Pushing the Boundaries of Surgical Possibility

While global access forms the foundation of its mission, SS Innovations is also pushing the technical boundaries of what is possible in surgery. Two recent achievements stand out: a landmark pediatric procedure and a new world record in telesurgery. In August, surgeons at an Indian hospital utilized the SSi Mantra’s specialized 5-millimeter instruments to perform a delicate robotic pyeloplasty—a complex kidney reconstruction—on a 45-day-old infant. The successful procedure and rapid recovery of such a small patient underscore the system’s precision and control, critical capabilities for the burgeoning field of pediatric robotic surgery, where the company has now enabled over 250 procedures.

Even more striking was the successful robotic telesurgery performed between Colombia and India. A surgical team led by Dr. Srivastava, operating from a console in Bucaramanga, performed a sleeve gastrectomy on a patient over 13,600 miles away in Indore, India. This eclipses the company’s own previous record and serves as a powerful proof of concept for the future of remote healthcare. Achieving such a feat requires overcoming immense technical hurdles, including minimizing network latency to near-imperceptible levels and ensuring ironclad cybersecurity to protect the integrity of the procedure. With successful telesurgery launches also occurring within the Philippines and a cumulative total of 188 remote procedures completed, SS Innovations is building a viable ecosystem for surgery without borders, a development with profound implications for providing specialist care to remote and underserved areas.

The Challenger's Ascent: A New Force in a Consolidated Market

Underpinning these clinical and technological feats is a story of remarkable business momentum. With its installed base growing 42% and procedures completed skyrocketing by 79% since the end of 2025, SS Innovations is rapidly scaling its operations. The reported total of over 14,000 successful procedures performed by approximately 1,500 trained physicians across 170 different procedure types speaks to the system's versatility and growing acceptance within the medical community. The feat of one hospital completing 50 robotic surgeries in a single day using five SSi Mantra systems demonstrates a robustness and efficiency that is critical for high-volume health systems.

This rapid ascent positions the company as a formidable challenger in a market long dominated by a few established, high-cost players. Its strategy appears to be a patient and calculated one: establish a dominant position in cost-sensitive markets while diligently working through the stringent regulatory processes of the United States and Europe. The company anticipates a decision on its FDA 510(k) submission by the first quarter of 2027 and a European CE marking certification by the end of 2026. While these timelines represent a slight revision from earlier projections, they reflect the rigorous and often lengthy realities of medical device approval for complex systems. Achieving these certifications would open the largest and most lucrative healthcare markets in the world, providing a pivotal test for the company’s ambition to truly globalize affordable robotic surgery.